Adcentrx Therapeutics is a biotechnology company developing Antibody-Drug Conjugate (ADC) therapeutics for cancer and other life‑threatening diseases. The company combines biologic targeting with small‑molecule payloads using its proprietary i‑Conjugation™ technology. Its lead ADC candidate, ADRX-0706, targets Nectin-4 and uses a novel tubulin inhibitor payload, AP052, yielding a drug‑antibody ratio of eight (DAR 8). ADRX-0706 showed favorable pharmacokinetic and safety profiles and significant efficacy in preclinical models and is currently being evaluated in a Phase 1a/b clinical trial. Adcentrx intends to use the newly raised funds to continue advancing its proprietary ADC pipeline in the clinic. The company is led by founder and CEO Hui Li and operates in San Diego and Shanghai. Adcentrx Therapeutics is based in San Diego, CA and Shanghai, China and develops antibody-drug conjugates (ADCs) that combine the targeting precision of biologics with the disease‑fighting power of small‑molecule payloads. The company’s lead candidate, ADRX-0706, is anticipated to enter a first-in-human Phase 1 clinical trial in the second half of 2023. Adcentrx is advancing additional ADC candidates in parallel with the goal of advancing at least one into the clinic each year. The company intends to use proceeds from the financing to advance its proprietary ADC therapeutic pipeline into the clinic. Adcentrx is led by founder and CEO Hui Li, Ph.D.

Total raised

$51M

Funding rounds

2

Latest round

Series A

Latest activity

Dec 2023